GlassScriptPhysician profile
Alina A Gover
NPI 1861449977
$4,200.53
in general payments reported to CMS, 2019-2025
30 companies · $951 in 2025
The $951 reported for 2025 was more than what 84% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $935 · 2020: $290 · 2021: $352 · 2022: $329 · 2023: $321 · 2024: $1,023 · 2025: $951.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,295.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,294.96 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $685.31 | 2019-2025 | Breztri, Farxiga, Airsupra |
| Abbvie INC. | $525.20 | 2020-2025 | |
| Lilly USA, LLC | $498.92 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Astellas Pharma US INC | $310.04 | 2019-2025 | Veozah |
| Pfizer INC. | $230.76 | 2019-2025 | |
| Glaxosmithkline, LLC. | $210.36 | 2024 | Arexvy, Trelegy Ellipta |
| Indivior INC. | $167.74 | 2024-2025 | Sublocade |
| Amgen INC. | $165.55 | 2020-2025 | Evenity, Otezla, Repatha |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $161.78 | 2024-2025 | Caplyta |
| Alkermes, INC. | $158.79 | 2019-2025 | Lybalvi |
| Teva Pharmaceuticals USA, INC. | $144.02 | 2020-2023 | Austedo Xr |
| Kvk-Tech, INC. | $126.81 | 2024-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $107.82 | 2020-2022 | |
| Abbott Laboratories | $91.71 | 2021-2022 | |
| Novartis Pharmaceuticals Corporation | $77.93 | 2019 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $73.55 | 2019 | |
| Exact Sciences Corporation | $60.08 | 2025 | The Cologuard Plus Collection Kit, Cologuard Collection Kit |
| Merck Sharp & Dohme LLC | $57.19 | 2019-2023 | Verquvo, Steglatro, Belsomra |
| Otsuka America Pharmaceutical, INC. | $52.51 | 2023-2024 | Rexulti |
| Phathom Pharmaceuticals, INC. | $44.47 | 2024-2025 | Voquezna |
| Braeburn INC. | $33.24 | 2024 | Brixadi |
| Novo Nordisk INC | $32.85 | 2022-2025 | |
| Biohaven Pharmaceuticals, INC. | $32.58 | 2021 | |
| Biohaven Pharmaceutical Holding Company LTD. | $31.97 | 2022 | |
| Sanofi Pasteur INC. | $31.35 | 2019-2020 | |
| Kowa Pharmaceuticals America, INC. | $29.09 | 2022-2023 | Livalo, Seglentis |
| Amarin Pharma, INC. | $16.26 | 2020 | |
| Evofem Biosciences, INC. | $16.06 | 2024 | |
| Xeris Pharmaceuticals, INC. | $14.83 | 2023 | Gvoke Hypopen |
| Allergan, INC. | $11.76 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alina Gover listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.